Ravi Paluri to Pancreatic Neoplasms
This is a "connection" page, showing publications Ravi Paluri has written about Pancreatic Neoplasms.
Connection Strength
2.926
-
Manne A, Kasi A, Esnakula AK, Paluri RK. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. Int J Mol Sci. 2023 Apr 30; 24(9).
Score: 0.815
-
Paluri R, Laursen A, Gaeta J, Wang S, Surinach A, Cockrum P. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States. Oncologist. 2022 Jun 08; 27(6):e518-e523.
Score: 0.766
-
Alkashash AM, Elsebaie MA, Bikhet MH, Morsi M, Paluri RK. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience. Chirurgia (Bucur). 2021 Jan-Feb; 116(1):24-33.
Score: 0.694
-
Paluri RK, Kasi A, Young C, Posey JA. Second-line treatment for metastatic pancreatic cancer. Clin Adv Hematol Oncol. 2020 Feb; 18(2):106-115.
Score: 0.651